Achieve Life Sciences, Inc. (ACHV) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-24

How it makes money

Patients will pay for cytisinicline as a treatment for smoking cessation.

Patients pay for cytisinicline to help them stop smoking; successful regulatory approval of its drug application drives this result.

The company is targeting the global nicotine dependence epidemic, focusing on both combustible cigarettes and e-cigarettes.

What protects it: the moat

Management claims its version of the drug is better than others.

The company asserts that cytisinicline is differentiated from existing treatments by its efficacy, safety profile, and dosing flexibility.

It also holds an exclusive license for the development and commercialization of the drug outside of Sopharma's territories.

What growth costs

It must raise massive amounts of cash to reach commercial launch.

The company requires substantial capital to fund clinical development, regulatory approval processes, and manufacturing.

It also needs to invest in expanding its commercialization activities and adding the personnel necessary to operate as a commercial-stage company.

What could damage it

Manufacturing issues at its partner's facility could prevent the company from selling its drug.

The company relies on a third-party manufacturer to produce its drug product.

If that manufacturer cannot resolve current FDA observations regarding its manufacturing processes, the company may be unable to provide the drug to the market.

About Achieve Life Sciences, Inc.

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

Other companies in Biotechnology